Press coverage about Gemphire Therapeutics (NASDAQ:GEMP) has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.5526905726093 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Gemphire Therapeutics (NASDAQ GEMP) remained flat at $9.64 during mid-day trading on Friday. The stock had a trading volume of 30,725 shares. The firm has a 50 day moving average price of $13.20 and a 200 day moving average price of $11.42. Gemphire Therapeutics has a one year low of $7.20 and a one year high of $21.59. The company’s market capitalization is $102.43 million.

Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by $0.28. Equities research analysts expect that Gemphire Therapeutics will post ($3.18) EPS for the current fiscal year.

Several brokerages recently issued reports on GEMP. Zacks Investment Research lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Canaccord Genuity set a $31.00 price objective on shares of Gemphire Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 8th. Jefferies Group LLC boosted their price objective on shares of Gemphire Therapeutics to $32.00 and gave the company a “buy” rating in a report on Tuesday, August 1st. Finally, HC Wainwright began coverage on shares of Gemphire Therapeutics in a report on Thursday. They issued a “buy” rating and a $21.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $23.86.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Receive News & Stock Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related stocks with our FREE daily email newsletter.